Results of early clinical trials with both topical treatment with cipamfylline [10] and systemic treatment with atizoram (CP-80,633) [12] or apremilast [8] demonstrated efficacy of PDE4 inhibitors in atopic dermatitis and psoriasis. Here, PDE4A is linked to atopic eczema.